Oxidation of Biginelli Reaction
Products: Synthesis of 2-Unsubstituted 1,4-Dihydropyrimidines,
Pyrimidines, and 2-Hydroxypyrimidines

Sam Sik Kim; Bo Seung Choi; Jae Hoon Lee; Ki Kon Lee; Tae Hee Lee; Young Ho Kim; Hyunik Shin

doi:10.1055/s-0028-1087920

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000083.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Synlett 2009(4): 599-602
DOI: 10.1055/s-0028-1087920

LETTER

Oxidation of Biginelli Reaction Products: Synthesis of 2-Unsubstituted 1,4-Dihydropyrimidines, Pyrimidines, and 2-Hydroxypyrimidines

Sam Sik Kim^a, Bo Seung Choi^a, Jae Hoon Lee^a, Ki Kon Lee^a, Tae Hee Lee^a, Young Ho Kim^b, Hyunik Shin*^a
^a Chemical Development Division, LG Life Sciences, Ltd./R&D, 104-1, Moonji-dong, Yusong-gu, Daejon 305-380, Korea
Fax: +82(42)8665754; e-Mail: hisin@lgls.com;
^b Department of Fine Chemical Engineering & Applied Chemistry, BK21-E2M, Chungnam National University, Daejeon 305-764, Korea

Further Information

Publication History

Received 28 October 2008
Publication Date:
16 February 2009 (online)

Abstract
Full Text
References

Permissions and Reprints All articles of this category

Abstract

We have devised a new route toward 2-unsubstituted pyrimidine derivatives from the Biginelli product, dihydropyrimidin-2(1H)-thiones in two steps: Oxidation of dihydropyrimidin-2(1H)-thiones using oxone on wet alumina or hydrogen peroxide in the presence of catalytic amount of vanadyl sulfate provided 1,4-dihydropyrimidine, which was further oxidized to 2-unsubstituted pyrimidines by the treatment of KMnO₄. Oxidation of dihydropyrimidin-2(1H)-ones by KMnO₄ formed 2-hydroxypyrimidine in excellent yield, whereas attempted direct desulfurative aromatization of dihydropyrimidin-2(1H)-thiones by KMnO₄ resulted in the formation of 2-hydroxypyrimidines, the same products obtained in the oxidation of dihydropyrimidin-2(1H)-one.

Key words

Biginelli reaction - desulfurative oxidation - 2-unsubstituted pyrimidine - 1,4-dihydropyrimidine - 2-hydroxypyrimidine

References and Notes

1 Kappe CO. Eur. J. Med. Chem. 2000, 35: 1043

Crossref PubMed Google Scholar
2 Ranu BC. Hajra A. Jana U. J. Org. Chem. 2000, 65: 6270

Crossref PubMed Google Scholar
3 Fu NY. Yuan YF. Cao Z. Wang SW. Wang JT. Peppe C. Tetrahedron 2002, 58: 4801

Crossref Google Scholar
4 Bose DS. Fatima L. Mereyala HB. J. Org. Chem. 2003, 68: 587

Crossref Google Scholar
5 Ramalinga K. Vijayalakshmi P. Kaimala TNB. Synlett 2001, 863

Article in Thieme Connect Google Scholar
6 Rafiee E. Jafari H. Bioorg. Med. Chem. Lett. 2006, 16: 2463

Crossref Google Scholar
7 Yadav JS. Reddy BVS. Srinivas R. Venugopal C. Ramalingam T. Synthesis 2001, 1341

Article in Thieme Connect Google Scholar
8 Zhu YL. Huang SL. Pan YJ. Eur. J. Org. Chem. 2005, 2354

Crossref Google Scholar
9 Sabitha G. Reddy GKK. Reddy CS. Yadav JS. Synlett 2003, 858

Article in Thieme Connect Google Scholar
10 Lu J. Ma H. Synlett 2000, 63

Article in Thieme Connect Google Scholar
11 Abelman MM. Smith SC. James DR. Tetrahedron Lett. 2003, 44: 4559

Crossref Google Scholar
12 Lu J. Bai Y. Wang Z. Yang B. Ma H. Tetrahedron Lett. 2000, 41: 9075

Crossref Google Scholar
13 Hu EH. Sidler DR. Dolling UH. J. Org. Chem. 1998, 63: 3454

Crossref Google Scholar
14 Mitsushita A, Oda M, Kawachi Y, and Chika J.-i. inventors; WO 03006437.
15 Watanabe M. Koike H. Ishiba T. Okada T. Seo S. Hirai K. Bioorg. Med. Chem. 1997, 5: 437

Crossref Google Scholar
16 Kappe CO. Roschger P. J. Heterocycl. Chem. 1989, 26: 1555 ; this Pd/C dehydrogenation without the use of oxidant requires rigorous conditions (210 ˚C) in Ph₂O

Crossref Google Scholar
17 Kadis V. Strandins J. Khanina EL. Duburs G. Electrochim. Acta 1989, 34: 899

Crossref Google Scholar
18 Yamamoto K. Chen YG. Buono FG. Org. Lett. 2005, 7: 4673

Crossref Google Scholar
19 Karade NN. Gampawar SV. Kondre JM. Tiwari GB. Tetrahedron Lett. 2008, 49: 6698

Crossref Google Scholar
20a Kress TJ. Heterocycles 1994, 38: 1380

Google Scholar
20b Draper RW. inventors; WO 2005007608.
20c Palani A. Shapiro S. Clader JW. Greenlee WJ. Vice SF. McCombie S. Cox K. Stizki J. Baroudy BM. Bioorg. Med. Chem. Lett. 2003, 13: 709

Google Scholar
20d McCombie SW. Tagat JR. Vice SF. Lin S.-I. Steensma R. Palani A. Neustadt BR. Baroudy BM. Strizki JM. Enders M. Cox K. Dan N. Chou C.-C. Bioorg. Med. Chem. Lett. 2003, 13: 567

Google Scholar
21a Khanina EL. Zolotoyabko RM. Muceniece D. Duburs G. Khim. Geterotsikl. Soedin. 1989, 1076

Google Scholar
21b Kanina EL. Mucenice D. Kadysh VP. Duburs G. Khim. Geterotsikl. Soedin. 1986, 1223 ; in these references, pyrimidin-2-thione or its thioether derivative was reduced by Raney nickel to provide 1,4-dihydropyrimidine

Google Scholar
22 Chang JH. Lee KW. Nam DH. Kim WS. Shin H. Org. Process Res. Dev. 2002, 6: 674

Crossref Google Scholar
23 Greenhalgh RP. Synlett 1992, 235

Article in Thieme Connect Google Scholar
25a Girke WPK. Chem. Ber. 1979, 112: 1

Google Scholar
25b de Bie DA. Nagel A. van der Plas HC. Koudijs A. Tetrahedron Lett. 1979, 649

Google Scholar

24

General Procedure for the Preparation of 1,4-Dihydro-pyrimidines 2a-e To a stirred mixture of 1a (1 g, 3.62 mmol) and a catalytic amount of vanadium sulfate (0.0072 g, 10 mol%) in EtOH (2.5 mL) and H₂O (2.5 mL) was added dropwise 30% H₂O₂ (1.52 g, 13.38 mmol) over 1 h maintaining the reaction temperature at about 50 ˚C. After 8-12 h, the mixture was cooled and volatiles were evaporated under vacuum. The mixture was diluted with CH₂Cl₂ (10 mL) and washed with H₂O (30 mL). The separated organic layer was dried with MgSO₄, filtered, and concentrated to afford crude 2a. Column chromatography with EtOAc-n-hexane gave 2a as a white solid (397 mg, 48%).
Spectroscopic Data
Compound 2a: ^¹H NMR (400 MHz, DMSO-d ₆): δ = 9.30 (s, 1 H), 7.30-7.16 (m, 5 H), 5.40 (s, 1 H), 3.97 (q, J = 4.0 Hz, 2 H), 2.22 (s, 3 H), 1.12 (t, J = 2.7 Hz, 3 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 167.4, 145.6, 143.3, 128.9, 127.7, 127.6, 100.7, 60.2, 58.0, 19.3, 14.6. ESI-MS: m/z = 245.3 [M + 1].
Compound 2b: ^¹H NMR (400 MHz, CDCl₃): δ = 8.27 (br s, 1 H), 7.26-6.92 (m, 4 H), 5.48 (s, 1 H), 4.08 (q, J = 4.0 Hz, 2 H), 2.62 (q, J = 4.0 Hz, 2 H), 2.22 (s, 3 H), 1.26-1.15 (m, 6 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 167.3, 145.6, 144.4, 143.9, 142.8, 128.4, 127.5, 101.0, 60.2, 57.2, 28.9, 18.8, 15.8, 14.6. ESI-MS: m/z = 273.4 [M + 1].
Compound 2c: ^¹H NMR (400 MHz, CDCl₃): δ = 10.13 (s,
1 H), 9.91 (s, 1 H), 4.83 (t, J = 4.0 Hz, 1 H), 4.26 (m, 2 H), 2.48 (s, 3 H), 1.79-1.14 (m, 11 H), 0.87 (t, J = 2.7 Hz, 3 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 164.3, 161.1, 142.7, 107.4, 61.7, 52.5, 51.7, 47.0, 36.9, 31.6, 23.3, 22.7, 17.9, 14.6, 14.3. ESI-MS: m/z = 239.3 [M + 1].
Compound 2d: ^¹H NMR (400 MHz, CDCl₃): δ = 7.43 (s,
1 H), 7.28-7.14 (m, 5 H), 4.63 (t, J = 4.0 Hz, 1 H), 4.18 (m, 2 H), 2.80-2.67 (m, 2 H), 2.28 (s, 3 H), 1.91-1.82 (m, 2 H), 1.26 (t, J = 3.3 Hz, 3 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 175.9, 165.8, 165.7, 144.5, 141.1, 128.9, 128.7, 126.5, 103.2, 103.1, 60.8, 60.4, 52.3, 38.3, 30.9, 18.6, 14.7. ESI-MS: m/z = 271.4 [M + 1].
Compound 2e: ^¹H NMR (400 MHz, CDCl₃): δ = 7.34-6.99 (m, 4 H), 5.57 (s, 1 H), 5.40 (d, J = 4.0 Hz, 1 H), 4.09 (m,
2 H), 2.31 (s, 3 H), 1.20 (t, J = 2.7 Hz, 3 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 167.1, 162.5 (d, J = 250.0 Hz), 145.1, 142.6, 141.4, 129.2 (d, J = 10.0 Hz), 115.6 (d, J = 20.0 Hz), 115.5, 101.2, 60.3, 57.4, 19.5, 14.6. ESI-MS: m/z = 263.3 [M + 1].

26

General Procedure for the Preparation of 2-Unsubsti-tuted Pyrimidines 3a-e To a stirred solution of 2a (100 mg, 0.41 mmol) in acetone (2 mL) was added KMnO₄ (87 mg, 0.55 mmol). After the complete consumption of 2a, excess of KMnO₄ was decomposed by the addition of 2-PrOH. The reaction mixture was filtered through Celite and washed thoroughly with acetone (10 mL). Removal of solvent afforded product 3a (72mg, 73%) as a white solid.
Spectroscopic Data
Compound 3a: ^¹H NMR (400 MHz, CDCl₃): δ = 9.16 (s, 1 H), 7.68-7.43 (m, 5 H), 4.24 (q, J = 4.0 Hz, 2 H), 2.57 (s, 3 H), 1.10 (t, J = 2.7 Hz, 3 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 167.4, 164.7, 162.9, 157.8, 137.2, 131.8, 131.5, 129.9, 128.3, 128.0, 125.7, 61.7, 22.3, 13.4. ESI-MS: m/z = 243.4 [M + 1].
Compound 3b: ^¹H NMR(400 MHz, CDCl₃): δ = 9.13 (s, 1 H), 7.60 (d, J = 4.0 Hz, 2 H), 7.37 (d, J = 4.0 Hz, 2 H), 4.26 (q, J = 4.0 Hz, 2 H), 2.73 (q, J = 4.0 Hz, 2 H), 2.62 (s, 3 H), 1.28 (t, J = 2.7 Hz, 3 H), 1.13 (t, J = 2.7 Hz, 3H). ^¹³C NMR (100 MHz, CDCl₃): δ = 168.3, 165.2, 163.6, 158.4, 147.2, 135.8, 128.8, 128.6, 126.2, 62.3, 29.1, 22.9, 15.8, 14.1. ESI-MS: m/z = 271.3 [M + 1].
Compound 3c: ^¹H NMR (400 MHz, CDCl₃): δ = 9.01 (s, 1 H), 4.48 (q, J = 4.0 Hz, 2 H), 2.79 (t, J = 4.0 Hz, 2 H), 2.54 (s, 3 H), 1.77-1.22 (m, 9 H), 0.92 (t, J = 2.7 Hz, 3 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 167.8, 167.7, 164.2, 158.3, 62.2, 36.1, 31.9, 28.9, 22.9, 22.7, 14.4, 14.2. ESI-MS: m/z = 237.3 [M + 1].
Compound 3d: ^¹H NMR (400 MHz, CDCl₃): δ = 9.02 (s, 1 H), 7.40-7.00 (m, 5 H), 4.44 (q, J = 4.0 Hz, 2 H), 3.11-3.02 (m, 4 H), 2.54 (s, 3 H), 1.40 (t, J = 3.3 Hz, 3 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 167.6, 166.8, 164.6, 158.5, 128.9, 128.8, 127.2, 126.7, 62.4, 38.2, 35.3, 23.2, 14.6. ESI-MS:
m/z = 271.4 [M + 1].
Compound 3e: ^¹H NMR (400 MHz, CDCl₃): δ = 9.14 (s, 1 H), 7.70-7.65 (m, 2 H), 7.21-7.11 (m, 2 H), 4.27 (q, J = 4.0 Hz, 2 H), 2.63 (s, 3 H), 1.18 (t, J = 2.7 Hz, 3 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 168.1, 164.4 (d, d, J = 230.0 Hz), 164.0, 162.4, 158.5, 134.0, 131.0 (d, J = 10.0 Hz), 126.2, 116.2 (d, J = 20.0 Hz), 62.5, 23.0, 14.1. ESI-MS: m/z = 261.3 [M + 1].

27

General Procedure for the Preparation of 2-Hydroxy-pyrimidines 5a-e To a stirred solution of 4a (1.0 g, 3.84 mmol) in acetone (20 mL) was added KMnO₄ (1.52 g, 9.60 mmol). After the complete consumption of 4a, the excess KMnO₄ was decomposed by the addition of 2-PrOH. The reaction mixture was filtered through Celite and washed thoroughly with acetone (30 mL). Removal of solvent afforded product 5a (670mg, 81%) as a white solid.
Spectroscopic Data
Compound 5a: ^¹H NMR (400 MHz, CDCl₃): δ = 7.61-7.41 (m, 5 H), 4.05 (q, J = 4.0 Hz, 2 H), 2.62 (s, 3 H), 0.94 (t, J = 2.7 Hz, 3 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 167.4, 164.7, 162.9, 157.8, 137.2, 131.8, 131.7, 131.5, 129.9, 128.3, 128.0, 125.7, 61.7, 22.3, 13.4. ESI-MS: m/z = 259.3 [M + 1].
Compound 5b: ^¹H NMR (400 MHz, CDCl₃): δ = 7.52-7.13 (m, 4 H), 4.80-4.26 (m, 2 H), 3.01 (q, J = 4.0 Hz, 2 H), 2.84 (s, 1 H), 2.69-2.45 (m, 2 H), 2.30 (s, 3 H), 1.26 (t, J = 2.7 Hz, 3 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 165.8, 141.0, 140.4, 129.0, 128.8, 128.7, 126.9, 126.8, 62.2, 38.8, 31.8, 31.0, 30.7, 30.1, 25.5, 14.6. ESI-MS: m/z = 287.3 [M + 1].
Compound 5c: ^¹H NMR (400 MHz, CDCl₃): δ = 4.42 (q, J = 2.0 Hz, 2 H), 2.80 (t, J = 2.0 Hz, 2 H), 2.53 (s, 3 H), 1.73-1.26 (m, 9 H), 0.90 (t, J = 2.7 Hz, 3 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 166.0, 158.7, 111.8, 62.1, 32.0, 31.8, 31.5, 22.8, 14.6, 14.29, 14.26. ESI-MS: m/z = 253.3 [M + 1].
Compound 5d: ^¹H NMR (400 MHz, CDCl₃): δ = 7.52-7.13 (m, 5 H), 4.80-4.26 (m, 2 H), 3.01 (q, J = 4.0 Hz, 2 H), 2.84 (s, 1 H), 2.69-2.45 (m, 2 H), 2.30 (s, 3 H), 1.26 (t, J = 2.7 Hz, 3 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 175.9, 165.8, 165.7, 144.5, 141.1, 128.9, 128.7, 126.5, 103.2, 103.1, 60.8, 52.3, 38.3, 30.9, 18.6, 14.7. ESI-MS: m/z = 287.3 [M + 1].
Compound 5e: ^¹H NMR (400 MHz, CDCl₃): δ = 7.65-6.97 (m, 4 H), 4.11 (q, J = 4.0 Hz, 2 H), 2.62 (s, 3 H), 1.02 (t, J = 2.7 Hz, 3 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 165.5, 162.4 (d, J = 250.0 Hz), 146.4, 139.7, 139.6, 128.4 (d, J = 10.0 Hz), 115.5 (d, J = 20.0 Hz), 101.4, 60.1, 55.0, 18.5, 14.2. ESI-MS: m/z = 277.3 [M + 1].